vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 39.4%, a 26.4% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 17.5%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 18.1%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
FNLC vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $18.6M |
| Net Profit | $10.2M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 48.1% | 56.3% |
| Net Margin | 39.4% | 65.7% |
| Revenue YoY | 17.5% | 1808.5% |
| Net Profit YoY | 39.7% | 376.5% |
| EPS (diluted) | $0.91 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $18.6M | ||
| Q3 25 | $24.5M | $334.0K | ||
| Q2 25 | $22.5M | $1.4M | ||
| Q1 25 | $21.8M | $257.0K | ||
| Q4 24 | $22.0M | $977.0K | ||
| Q3 24 | $20.5M | $660.0K | ||
| Q2 24 | $19.2M | $736.0K | ||
| Q1 24 | $18.5M | $1.4M |
| Q4 25 | $10.2M | $12.3M | ||
| Q3 25 | $9.1M | $-8.6M | ||
| Q2 25 | $8.1M | $-6.9M | ||
| Q1 25 | $7.1M | $-5.4M | ||
| Q4 24 | $7.3M | — | ||
| Q3 24 | $7.6M | $-2.8M | ||
| Q2 24 | $6.2M | $-14.5M | ||
| Q1 24 | $6.0M | $411.0K |
| Q4 25 | 48.1% | 56.3% | ||
| Q3 25 | 45.2% | -2516.5% | ||
| Q2 25 | 43.7% | -701.0% | ||
| Q1 25 | 39.3% | -3350.2% | ||
| Q4 24 | 39.5% | — | ||
| Q3 24 | 44.6% | -1563.6% | ||
| Q2 24 | 38.8% | -1255.0% | ||
| Q1 24 | 39.3% | -692.5% |
| Q4 25 | 39.4% | 65.7% | ||
| Q3 25 | 37.0% | -2572.2% | ||
| Q2 25 | 35.8% | -504.8% | ||
| Q1 25 | 32.5% | -2097.7% | ||
| Q4 24 | 33.1% | — | ||
| Q3 24 | 36.9% | -425.5% | ||
| Q2 24 | 32.1% | -1964.4% | ||
| Q1 24 | 32.5% | 29.9% |
| Q4 25 | $0.91 | $0.25 | ||
| Q3 25 | $0.81 | $-0.17 | ||
| Q2 25 | $0.72 | $-0.14 | ||
| Q1 25 | $0.63 | $-0.11 | ||
| Q4 24 | $0.66 | — | ||
| Q3 24 | $0.68 | $-0.06 | ||
| Q2 24 | $0.55 | $-0.30 | ||
| Q1 24 | $0.54 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $95.5M | — |
| Stockholders' EquityBook value | $283.1M | $49.4M |
| Total Assets | $3.2B | $59.0M |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $95.5M | — | ||
| Q3 25 | $95.5M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | $95.0M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.0M | — | ||
| Q1 24 | $70.0M | — |
| Q4 25 | $283.1M | $49.4M | ||
| Q3 25 | $274.6M | $36.4M | ||
| Q2 25 | $265.5M | $44.5M | ||
| Q1 25 | $259.7M | $50.5M | ||
| Q4 24 | $252.5M | $55.1M | ||
| Q3 24 | $256.8M | $58.5M | ||
| Q2 24 | $244.7M | $60.4M | ||
| Q1 24 | $242.6M | $74.1M |
| Q4 25 | $3.2B | $59.0M | ||
| Q3 25 | $3.2B | $51.1M | ||
| Q2 25 | $3.2B | $60.7M | ||
| Q1 25 | $3.2B | $67.9M | ||
| Q4 24 | $3.2B | $90.6M | ||
| Q3 24 | $3.1B | $99.0M | ||
| Q2 24 | $3.1B | $107.8M | ||
| Q1 24 | $3.0B | $118.3M |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $18.4M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 133.9% | — |
| Capex IntensityCapex / Revenue | 12.5% | — |
| Cash ConversionOCF / Net Profit | 3.72× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $18.4M | ||
| Q3 25 | $12.9M | $-8.7M | ||
| Q2 25 | $7.4M | $-7.5M | ||
| Q1 25 | $2.2M | $-7.5M | ||
| Q4 24 | $26.0M | $-24.0M | ||
| Q3 24 | $9.8M | $765.0K | ||
| Q2 24 | $6.4M | $-10.9M | ||
| Q1 24 | $-1.5M | $-4.0M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $12.6M | — | ||
| Q2 25 | $7.2M | — | ||
| Q1 25 | $828.0K | — | ||
| Q4 24 | $24.6M | — | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | 133.9% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 32.1% | — | ||
| Q1 25 | 3.8% | — | ||
| Q4 24 | 111.7% | — | ||
| Q3 24 | 47.0% | — | ||
| Q2 24 | 32.9% | — | ||
| Q1 24 | -9.8% | — |
| Q4 25 | 12.5% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 6.2% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 3.72× | 1.50× | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
